Product
SB16
1 clinical trial
1 indication
Indication
OsteoporosisClinical trial
A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Between SB16 (Proposed Denosumab Biosimilar) and Prolia® in Postmenopausal Women With OsteoporosisStatus: Completed, Estimated PCD: 2022-06-20